New shot could tame severe hay fever symptoms
NCT ID NCT06300203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new antibody drug for people whose seasonal allergies (hay fever) are not controlled by standard treatments. The drug targets a protein involved in allergic inflammation. About 120 adults will receive either the antibody or a placebo, and researchers will measure changes in nasal symptoms like sneezing and congestion after two weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pinpoint pollen dose unmask allergy triggers?
- New allergy pill could offer relief from sneezing and stuffy nose
- New injection could tame seasonal allergy symptoms for those failed by standard treatments
- New shot for teen hay fever? early trial underway
- Nasal spray test could make allergy shots smarter and cheaper
- New allergy drug AK139 aims to stop sneezing and stuffy noses